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Abstract 
 
The ovariectomized (OVX) rat, a preclinical model for studying 
postmenopausal bone loss, may also be used to study differences in alveolar bone 
(AB). The objectives of this study were to quantify the differences in AB following 
estrogen replacement therapy (ERT), and to investigate the relationship between AB 
structure and density, and trabecular bone at the femoral neck (FN) and third lumbar 
vertebral body (LB3). Estrogen treated rats had a higher bone volume fraction 
(BV/TV) at the AB region (9.8% P < 0.0001), FN (12% P < 0.0001), and LB3 
(11.5% P < 0.0001) compared to the OVX group. BV/TV of the AB was positively 
correlated with the BV/TV at the FN (r = 0.69 P < 0.0001) and the LB3 (r = 0.75 P < 
0.0001). The trabecular number (Tb.N), trabecular separation (Tb.Sp), and structure 
model index (SMI) were also positively correlated (P < 0.05) between the AB and FN 
(r = 0.42, 0.49, and 0.73, respectfully) and between the AB and LB3 (r = 0.44, 0.63, 
and 0.69, respectfully). Given the capacity of AB to respond to ERT, future 
preclinical drug/nutritional intervention studies aimed at improving skeletal health 
should include the AB as a region of interest (ROI). 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Osteoporosis 
 
 A decline in ovarian production of estrogens at menopause often results in a 
rapid loss of trabecular microarchitecture, increased endocortical bone resorption, and 
increased cortical porosity; all culminating in the development of osteoporosis and the 
associated increased risk for fragility fracture (Figure 1) [1]. Specifically, the number 
and activity of osteoclasts increases to a point where the rate of bone resorption 
exceeds the rate of bone formation [2]. 
 
 
Based on data from the WHO Global Burden of Disease project in 2000, an 
estimated 56 million people around the world experience disability caused by a 
fracture [3]. In 2010, there were 2.32 million new hip fractures in adults over 50 years 
of age worldwide, and approximately half of those hip fractures were due to 
osteoporosis in the FN [4]. Based on osteoporosis prevalence rates reported in the 
↓ Production of 
estrogen by 
ovaries
↑ Trabecular 
resorption
↑ Endocortical 
resorption
↑ Cortical porosity
↑ Risk of fragility 
fracture
Figure 1: Overview of how osteoporosis develops after menopause  
With the loss of endogenous estrogen production by the ovaries there is an increase in 
trabecular bone resorption, endocortical bone resorption and cortical porosity that 
elevates a woman’s risk of experiencing a fragility fracture. 
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2010 US Census and NHANES (2005-2010), it is estimated that 10.2 million 
Americans over the age of 50 have osteoporosis while an additional 43.4 million 
having low bone mass that predisposes them to the development of osteoporosis [5]. 
In Canada, it is estimated that 1 in 5 women and 1 in 10 men will experience a hip 
fracture during their life. Even when adjusting for annual trends in mortality and hip 
fracture, the estimated lifetime risk of hip fracture remains high at 8.9% for women 
and 6.7% for men [6]. With the average hip fracture hospitalization in Canada costing 
approximately $20,000, the financial burden of osteoporosis over the 2007-2008 
fiscal year was estimated at $2.3 billion dollars, or 1.3% of the entire Canadian 
healthcare budget [7]. It is well documented that women are disproportionally 
affected by osteoporosis compared to men, primarily due to the more sudden decline 
in estrogen production experienced at menopause whereas sex steroid levels decline 
more gradually in men [3-5, 8]. In the majority of postmenopausal women, the risk of 
experiencing a fragility fracture exceeds the risk of developing invasive breast cancer, 
stroke, and cardiovascular disease combined [9]. Moreover, there is substantive 
morbidity [10] associated with a fragility fracture and an increased risk of death; 
especially within the first year post-fracture [11]  
1.1.1 Osteoporosis, estrogen and tooth loss 
 
 Osteoporosis not only increases a woman’s risk of fragility fracture at the hip, 
spine and wrist, but is also associated with the loss of AB and teeth. [12-15]. For 
example, osteoporosis at the lumbar vertebrae, FN, or total hip is a significant 
predictor of molar tooth loss [12]. A 5-year longitudinal study of 404 postmenopausal 
women confirmed that women in the highest tertile of annual bone mineral density 
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(BMD) loss at the lumbar spine and FN had an adjusted relative risk of 1.38 and 1.27 
for tooth loss, respectively, compared to women in the lowest tertile of annual BMD 
loss. [13]. In a longitudinal study of even greater duration, 7 years, the relative risk of 
tooth loss in 180 postmenopausal women (serum 17-β estradiol (E2) < 25 pg/ml) was 
4.38 with each 1% annual decrease in whole body BMD [14]. A greater loss of AB 
height, and less alveolar crestal and subcrestal BMD – all critical for providing 
support for teeth – were also reported in a 2-year longitudinal study of 38 women 
with osteopenia and osteoporosis at the lumbar spine. Between the first and second 
molars in particular, estrogen-deficient (mean serum E2 < 30 pg/ml) women lost more 
alveolar crestal bone density compared to estrogen-sufficient (mean serum E2 > 40 
pg/ml) women [15]. Because tooth retention [16, 17] and functional dentition [18, 19] 
are key determinants of nutritional status the maintenance of AB is important for 
overall health. Risk of many chronic diseases such as obesity, type 2 diabetes, 
cardiovascular disease and some cancers is elevated by poor diet. Thus, strategies that 
preserve the skeleton at key sites of fragility fracture – hip, spine, wrist – as well as 
AB in the jaw are important for healthy aging. 
While ERT has been consistently shown to reduce fragility fractures at the 
hip, spine and wrist [20, 21] the effect on tooth retention and preserving AB has been 
less studied. However, a study of 42,171 postmenopausal women (aged ≤ 69 years) 
over a 2-year period as part of the Nurses’ Health Study cohort, reported that current 
use of hormone replacement therapy (HRT; estrogen alone, in combination with 
progestin, or progestin alone) was associated with a 24% decrease in the risk of tooth 
loss. In women using conjugated estrogen alone, at a dose of 0.3 mg per day, the risk 
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of tooth loss was 31% lower compared to non-users [22]. In a cohort of 3,921 older 
women, median age of 81 years, current ERT (with or without progesterone) was 
associated with a 27% lower risk of tooth loss [23]. Another study showed that a 
group of postmenopausal women (72-95 years of age) who used ERT (reported as any 
use of estrogen) for greater than 8 years retained an average of 3.6 more teeth than 
women who never used ERT [24]. The duration of ERT (estrogen alone or in 
combination with progestogen) was also a significant predictor of total and posterior 
teeth remaining in a group of 330 postmenopausal Japanese women [25]. The 
mechanism behind tooth retention and ERT remains unclear, but one 3-year 
longitudinal study of 135 women aged 41-70 years concluded that women receiving 
0.625 mg conjugated equine estrogen with or without 2.5 mg medroxyprogesterone 
acetate experienced a 0.9% increase in AB mass, as assessed by digitized radiographs, 
compared to non-users [26]. HRT or ERT may therefore work to increase the stability 
of the tooth-supporting AB and thereby promote tooth retention and the opportunity 
to consume a greater variety of foods.  
1.1.2 Tooth loss and nutritional status 
 
 Retention of natural teeth is associated with healthier nutrient intakes that may 
have a role in prevention of chronic disease. For example, dietary calcium (Ca) has 
been studied in relation to tooth loss because achieving recommended intakes of 
dietary Ca, in particular, is important for attenuating bone loss after menopause and 
during aging. As such, the recommended intake of Ca is 1200 mg per day in women 
aged 51-70 years and men over age 70 years [27]. Among older men and women (≥ 
65 years of age) with unknown smoking status, higher daily intake of Ca (884 versus 
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805 mg Ca) was associated with a greater number of teeth (≥ 21 versus 11-20 teeth) 
[16]. Another study reported lower tooth loss in a placebo-controlled 2-year study of 
non-smoking women taking a Ca supplement of 500 mg per day; smoking women 
were excluded because smoking is a risk factor for tooth loss [14].  
 Fruit and vegetable intake in relation to tooth loss has also been studied. Data 
from NHANES III, a large cross-sectional study of Americans over age 50, showed a 
reduced number of posterior teeth associated with a lower daily intake of the 
recommended amount of fruit servings as reflected in a lower Healthy Eating Index 
(HEI) score and a higher body mass index (BMI) [18]. Additionally, having no 
posterior teeth was associated with a lower daily intake of the recommended amount 
of vegetable servings, also reflected in a lower HEI score [18]. Even when controlling 
for socio-economic status, inadequate dentition (defined by < 21 teeth remaining) was 
associated with reduced intakes of fruit (stone fruits and grapes/berries) and vegetable 
(stir-fried or mixed vegetables, sweetcorn/corn on the cob, mushrooms, lettuce, and 
soy beans/tofu) in a sample of 530 dentate Australian men and women over the age of 
55 [19]. The link between tooth loss and reduced fruit and vegetable intake is 
important since a recent comprehensive review concluded that fruit and vegetable 
consumption was associated with a reduced risk of chronic diseases such as 
hypertension, coronary heart disease, and stroke [28]. Interestingly the relationship 
between a lower BMD in postmenopausal osteoporosis, higher rates of tooth loss, and 
lower fruit and vegetable intake comes full circle given the study of 670 
postmenopausal Chinese women that found higher fruit and vegetable intake was 
associated with greater whole body, lumbar spine, and hip BMD. The regression 
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model predicted that a daily increase of 100 g of fruits and vegetables was associated 
with a 6, 10, and 6 mg/cm2 greater BMD at the whole body, lumbar spine, and hip, 
respectively. [29].  
 The relationship between osteoporosis, tooth loss, and compromised nutrition 
may prove to be cyclical (Figure 2) since compromised nutrition could exacerbate 
osteoporosis. As discussed in section 1.1.1, HRT or ERT has been shown to promote 
tooth retention and may intervene in this self-perpetuating, negative cycle of tooth 
loss and the consequent greater risk of chronic disease development. Moreover, there 
are other pharmacological agents or diet interventions that may prove useful in 
stopping the cycle shown in Figure 2. The ovariectomized rat can be used to evaluate 
the effectiveness of an intervention for preserving AB [30, 31]. Findings from these 
studies provide an important step in developing interventions to promote and support 
bone health – including the retention of natural teeth – for postmenopausal women.  
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1.2. The ovariectomized rat model 
 
 The OVX rat model is an approved preclinical model by the Food and Drug 
Administration (FDA) [32] for studying how the decline in endogenous estrogen 
production by the ovaries at menopause leads to postmenopausal osteoporosis, and 
how potential interventions can preserve bone metabolism in this state. Although the 
FDA guidelines do not specify which strain of rat to use, it is important to be aware 
that there can be differences in BMD, bone size, and biomechanical bone strength 
among inbred rat strains [33]. Interventions include pharmacological agents as well as 
lifestyle strategies such as diet. By 12 weeks of age, the female Sprague-Dawley rat – 
among the most common strains studied – has reached sexual maturity and has 
Figure 2: Cyclical relationship among low BMD, tooth loss, compromised 
nutrition and risk for chronic disease 
ERT/HRT or other interventions that benefit other skeletal sites such as hip, spine 
and wrist may also prevent or slow the progression from low BMD to tooth loss. 
Retention of natural teeth allows individuals to eat a more healthful diet that is 
associated with a reduced risk of chronic disease. 
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achieved peak bone mass for the whole body, femora, and tibiae [34]. Peak bone mass 
was defined as the point at which the rat skeleton had accrued its greatest amount of 
areal BMD determined by dual-energy x-ray absorptiometry (DEXA) at the whole 
body, femur, and tibia. However, longitudinal bone growth continues in the female rat 
until the epiphyseal growth plates close. At 12 weeks of age, the distal tibia growth 
plate has closed while the proximal tibia, and lumbar vertebral growth plates remain 
open until 15, and 21 months respectively [35]. Despite the continued skeletal growth, 
rats are commonly ovariectomized at 12 weeks of age since the rats are sexually 
mature and therefore capable of modeling bone loss due to estrogen deficiency [36]. 
By 9 months of age, longitudinal bone growth at the proximal tibia metaphysis has 
slowed to 3 µm/day, while growth at the lumbar vertebral body has slowed to < 1 
µm/day [37]. 
Two developmental stages have been used to describe the adult rat skeleton: 
‘mature’ from 3-6 months of age and ‘aged’ ≥ 6 months of age. Skeletal growth is 
rapid from 1-3 months, reduced from 3-6 months and negligible past 6 months of age 
[38]. In addition to continued longitudinal bone growth, the extent of OVX-induced 
bone loss is dependent on both the skeletal site and the time since OVX. For example, 
in the proximal tibia, a significant decrease in trabecular bone volume (BV) is 
observed 2 weeks post-OVX compared to sham control with a plateau by 14 weeks 
post-OVX [39]. At the FN, a significant decrease in trabecular BV occurred at 4 
weeks post-OVX with a plateau by 39 weeks post-OVX [40]. The lumbar vertebrae 
was much more resistant to OVX-induced changes in trabecular BV than either the 
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proximal tibia or FN. It was not until 7 weeks post-OVX that a decrease in trabecular 
BV was significant and reached a plateau between 39 and 77 weeks post-OVX [41].  
The effect of time since OVX on the rat mandible is less clear so the studies 
discussed in this review are subsequently divided into those that are ≤ 12 weeks in 
duration and those that are ≥ 12 weeks duration after OVX. This time point was 
chosen since a 12-week period after OVX has been shown to be sufficient to decrease 
trabecular BV at the proximal tibia [39], FN [40], and lumbar vertebrae [41]. Figure 3 
is an image of a hemimandible from a Sprague-Dawley rat with key landmarks and 
directions highlighted and serves as a guide to the specific study regions of interest 
(ROI) discussed in the next section. Similarly, Figures 4 through 6 are included to 
assist the reader in identifying regions that have been analyzed in the studies that are 
discussed in this review. Figure 4 is a sagittal slice through the first molar (M1) with 
the interradicular septum containing AB highlighted. Figure 5 is a three-dimensional 
(3D) rendering of the 4 roots of M1 (mesial, lingual, buccal, and distal roots) and 
shows how these roots enclose the AB of the interradicular septum. Figure 6 is a 3D 
rendering of M1 in its bony socket and viewed as a cut-away to show landmarks used 
to define AB ROI. 
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Figure 3: Hemimandible from a 6-month old Sprague-Dawley rat  
From right to left: incisor, 1st molar (M1), 2nd molar (M2), 3rd molar (M3), the 
coronoid process and condyle. Mesial is the front, distal the back, buccal the 
lateral side, lingual the medial side and the coronal plane divides the mandible into 
mesial and distal portions. 
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Figure 4: Sagittal slice through molar 1 (M1) of a 6 month old Sprague-
Dawley rat with interradicular septum 
The interradicular septum is highlighted in red and extends from the furcation roof 
to the root apices. The occlusal surface of M1 is highlighted in blue and the 
arrowhead denotes the approximate location of the central sulcus. 
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Figure 5: Four roots of M1 
The mesial, distal, buccal, and lingual roots enclose the AB of the interradicular 
septum. 
 
13 
 
 
 
Figure 6: Landmarks to define ROI of AB at M1 
M1 in its bony socket (left) with the distance between the cemento-enamel junction 
(CEJ) and bone crest (pink), the mandibular canal (orange), and the incisor root 
(yellow). In a cut-away model of M1 in its bony socket (right) the AB of the 
interradicular septum (purple) is superior to the AB (red) between the incisor crest 
(blue) and mesial root apex (green). 
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1.2.1 Short-term effects of OVX on mandibular bone: findings from studies less 
than 12 weeks after OVX 
 
 In only three of the six studies with an OVX duration < 12 weeks, OVX 
reduced either AB structure [42, 43] or density [44] (Table 1). In those studies, the 
time since OVX was approximately nine weeks and the rats were ovariectomized at 
17, 25 and 26 weeks of age [42-44]. The first study [42] used histomorphometry to 
measure the M1 sagittal surface containing the central sulcus of the occlusal surface 
and both the mesial and distal root canals. The ROI was the entire interradicular 
septum of M1 extending from the furcation roof to the mesial and distal root apices 
(Figure 4). Relative to the sham group, there was lower BV and Tb.N with higher 
Tb.Sp but no difference in trabecular thickness (Tb.Th) between the sham and OVX 
group.  
 Similar results were reported by a study that also investigated AB nine weeks 
after OVX, the only difference being an older age at OVX, 25 versus 17 weeks [43]. 
The hemimandibles were scanned via micro-computed tomography (-CT) between 
the mesial and distal roots of M1 at a resolution of 50 m. The ROI was delineated 
inferiorly by a plane connecting the apices of the buccal and lingual roots (Figure 5), 
and superiorly by a contour along the interradicular septum (Figure 4). Relative to the 
sham group, there was less BV and Tb.Th with greater Tb.Sp. There was no 
difference in Tb.N between the sham and OVX group. 
 Changes in the AB density of Sprague-Dawley rats ovariectomized at 26 
weeks of age and maintained for the same nine weeks post-OVX were also reported 
[44]. To measure the tissue mineral density (TMD) distribution, hemimandibles were 
cut into 5 mm sections and scanned via -CT at a resolution of 20 m. The ROI was a 
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volume of AB extending 200 m from the surface of each tooth along the 5 mm 
section; if visualized in 3D the ROI would be a 200 µm thick cast of the tooth 
surfaces in direct contact with the AB. This ROI included both the periodontal 
ligament (~ 150 m) and the AB in direct contact with the tooth surface (~ 50 m). 
There were higher standardized grey values of the TMD distribution at the 5th 
percentile in the OVX group compared to the sham group. Higher grey values at the 
5th percentile implied more immature bone formation due to accelerated bone 
remodeling. There was also a higher standardized TMD distribution coefficient of 
variation (CV) in the OVX group compared to the sham group. A greater CV 
suggested that bone turnover increased. In summary, these studies have shown that by 
nine weeks post-OVX there is a reduced AB volume and increased Tb.Sp [42, 43] 
and the stability of the AB directly supporting the molars is also compromised [44].  
Of the studies with an OVX duration < 12 weeks, that did not report an effect 
on AB, two had times post-OVX of less than nine weeks [45, 46] and one had a time 
post-OVX of exactly nine weeks [47]. Different techniques used to measure changes 
to AB may also explain why, among the studies with an OVX duration of 
approximately 9 weeks, one study reported no effects [47] while three others reported 
effects [42-44]. The study with the shortest study period post-OVX measured 
mandibular BMD in Sprague-Dawley rats ovariectomized at four weeks of age and x-
ray radiographs of hemimandibles were taken four weeks after OVX [45]. The ROI 
began 1.5 cm mesial to M1 and extended until the end of the AB supporting the distal 
root of M3 (Figure 3). The ROI was delineated inferiorly by the crest of the incisor 
root and superiorly by the contours of the molar roots (Figure 6). This ROI included 
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the AB supporting M1-M3 and the surrounding cortical bone. There was no 
difference in BMD between the sham and OVX group. AB loss was also measured by 
calculating the difference in height between the CEJ and the bone crest at the 
midpoint of the mesial root (Figure 6) of each molar. There was no difference in AB 
loss between the sham and OVX group.  
 At five weeks post-OVX, the mandibular BMD of Sprague-Dawley rats 
ovariectomized at 13 weeks was measured using DEXA [46]. The ROI of left 
hemimandibles was a rectangle extending from the angle mesial to M1 until the distal 
root of M3 (Figure 3). The following were included in the ROI: molars, AB, cortical 
bone, and the incisor root. There was no difference in BMD between the sham and 
OVX group. Additionally, the mandibular bone area fraction and area moment of 
inertia were measured using coronal sections (Figure 3) of the distal most aspect of 
the M1 mesial root (Figure 5). An image of the newly exposed surface constituted the 
ROI and included the AB, cortical bone, and incisor root. There was no difference in 
bone area fraction or area moment of inertia between the sham and OVX group.  
  Even nine weeks after OVX, Wistar rats ovariectomized at 17 weeks of age 
showed no difference in the mandibular BMD between the sham and OVX group 
[47]. The mandibular BMD was measured by DEXA equipped with small animal 
software. The ROI was a rectangle encompassing the alveolar, condylar, and coronoid 
processes (Figure 3); the molar crowns and incisor were removed. Since changes in 
AB structure [42, 43] and density [44] have been reported by ~ nine weeks post-
OVX, it is possible that DEXA may not be sensitive enough to detect the OVX-
induced changes in the rat mandible. Studies that follow for a longer time period after 
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OVX are likely needed to detect OVX-induced loss of mandibular BMD by DEXA. 
Future studies that use µ-CT to measure changes in AB structure in response to OVX 
are also needed. It is likely that µ-CT would detect a more subtle change in AB after a 
shorter amount of time post-OVX than DEXA due to its superior resolution, ability to 
quantify structural changes, and highly specific ROI in 3D. Also, in order to detect a 
robust change in AB after OVX that can be correlated with changes at other typical 
skeletal sites such as the long bones and lumbar vertebrae, a time post-OVX of 
greater than 12 weeks is likely needed.
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AB, alveolar bone; BMD, bone mineral density; BV/TV, bone volume fraction; DEXA, dual-energy x-ray absorptiometry; Tb.N, 
trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; TMD, tissue mineral density; µ-CT, micro-computed 
tomography 
Table 1: Summary of studies investigating changes in mandibular health in rats less than 12 weeks after OVX 
Rat strain Sample 
size 
per group 
Age at 
OVX 
(wks) 
Time post-
OVX 
(wks) 
Diet Technology Main findings for mandible, 
compared to sham control 
Reference 
Sprague-
Dawley 
n = 5 4  4 0.89 % Ca Radiographs No change in BMD 
No AB loss 
[45] 
Sprague-
Dawley 
n = 8 13  5 1.00 % Ca DEXA, 
Histomorphometry 
Stereology 
No change in BMD, bone 
area fraction, or area 
moment of inertia 
[46] 
Fischer n = 8 17 9 Unknown Histomorphometry 25 % decrease in BV/TV 
17 % decrease in Tb.N 
32 % increase in Tb.Sp 
No change in Tb.Th 
[42] 
Sprague-
Dawley 
n = 10 26  9  Unknown µ-CT 7 % increase in the TMD 
distribution grey values at 
the 5th percentile  
25 % increase in the TMD 
distribution CV 
[44] 
Wistar n = 6 17  9  Unknown DEXA No change in BMD [47] 
Wistar n = 6 25  9 1.17 % Ca, 
0.91 % P 
 
µ-CT 15 % decrease in BV/TV 
14 % decrease in Tb.Th 
22 % increase in Tb.Sp 
No change in Tb.N 
[43] 
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1.2.2 Longer-term effects of OVX on mandibular bone: findings from studies that are 12 
weeks or longer after OVX 
 
 All of the studies with an OVX duration of longer than 12 weeks (Table 2) report a 
reduction in bone mineral and/or structural changes in AB. Of these nine studies, five reported 
changes in AB structure [48-52], three reported significant reductions in the BMD of AB [53-55] 
and a single study reported a decrease in the Ct.Th of AB [56]. 
 Two studies used conventional histomorphometric methods to report changes in AB 
structure following OVX [48, 51]. One study ovariectomized rats at six weeks of age and studied 
them until 12 weeks post-OVX [48]. To measure the mandibular histomorphometry, 
hemimandibles were sectioned coronally (Figure 3) into 50 m thick slices. The ROI was a 
rectangle, with an area of 0.135 mm2, inferior to the apices of the buccal and lingual roots of M1 
(Figure 5) and superior to the mandibular canal (Figure 6). There was a decrease in BV between 
the sham group and OVX group. Another study ovariectomized Sprague-Dawley rats at 26 weeks 
and maintained them for 29 weeks [51]. To measure the mandibular bone area fraction and the 
area moment of inertia, the left hemimandibles were sectioned coronally (Figure 3) between the 
mesial and buccal roots of M1 (Figure 5) and also between the roots of M2. The ROI for the bone 
area fraction was the entire surface of the M1 section with the molar crown/roots and incisor 
removed. The ROI for the area moment of inertia was the entire surface of the M2 section with 
the incisor removed. The bone area fraction of the OVX group was less than the sham group. 
There was no difference in the moment of inertia between sham and OVX groups.  
 The remaining three studies to report changes in AB structure used µ-CT [49, 50, 52]. To 
measure the mandibular morphometry of rats ovariectomized at 11 weeks and maintained for 16 
weeks, left hemimandibles were scanned via -CT beginning at the mesial plane of M1 and 
extending 25 slices toward the distal root (Figure 5); the scan was at a resolution of 15 m [49]. 
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The ROI was delineated superiorly by the apex of the M1 mesial root (Figure 5) and inferiorly by 
the crest of the incisor socket (Figure 6). The buccal and lingual walls of cortical bone that 
flanked the ROI were removed. Relative to the sham group, there was a lower BV, lower Tb.Th, 
higher Tb.Sp and a higher SMI in the OVX group. A higher SMI indicated a shift in trabeculae 
shape from plate-like to rod-like; rod-like trabeculae are thinner trabeculae and are thus indicative 
of structurally-compromised AB. 
 Another study measured the mandibular morphometry of rats ovariectomized at 28 weeks 
and studied 17 weeks later by scanning the left hemimandibles using -CT. This analysis was 
done between the mesial and distal borders of M1 (Figure 5) at a resolution of 16 m [50]. The 
ROI was an interpolated shape encompassing the AB from the apices of the buccal and lingual 
roots (Figure 5) to the crest of the incisor (Figure 6), and from the mesial to distal surfaces of the 
M1 interradicular septum (Figure 5). Relative to the sham group, there was a lower Tb.N and 
connectivity density in the OVX group but no differences in BV or Tb.Th between the sham and 
OVX group.  
 To investigate longer-term changes in mandibular morphometry, the right hemimandibles 
of rats ovariectomized at 26 weeks and studied 52 weeks later were scanned using -CT at a 
resolution of 20 m [52]. The ROI was the interradicular septum of M1 delineated inferiorly by a 
straight line between the mesial and distal roots (Figure 4). Only a single sagittal slice exposing 
the interradicular septum of M1 was used for the ROI, not the entire volume of the interradicular 
septum. Relative to the sham group there was a lower BV, a lower Tb.Th, a lower Tb.N, and a 
higher Tb.Sp in the OVX group – indicating compromised structure of AB.  
 Of the studies to evaluate changes in mandibular BMD following OVX using DEXA [50, 
51, 55], none reported any changes in BMD while each of the studies reported changes in 
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mandibular density or structure by either peripheral quantitative computed tomography (pQCT) 
[55], µ-CT [50] or histomorphometry [51]. Of the three studies to evaluate changes in mandibular 
density by pQCT, all three reported a loss of BMD post-OVX [53-55]. These studies provide 
evidence that mandibular BMD measured by DEXA cannot represent the changes in AB 
following OVX in the rat and that higher resolution techniques such as pQCT or µ-CT are 
needed. 
 In a study of rats ovariectomized at 35 weeks and studied at 13 weeks after OVX, the 
BMD of hemimandibles was measured via pQCT between the mesial root of M1 and the distal 
root of M2 (Figure 3) at a voxel size of 100 m and a section thickness of 750 m [53]. The ROI 
was the entire surface of each coronal section with the molar crowns, roots and the incisor root 
removed; this included both trabecular and cortical bone. Relative to the sham group, there was a 
lower total, trabecular and cortical bone mineral density (Ct.BMD) in the OVX group.  
 Another study in younger ovariectomized rats (13 weeks old) that were studied 16 weeks 
post-OVX, scanned hemimandibles using pQCT from the mesial border of M1 to the distal border 
of M3 (Figure 3) [55]. The ROI was the surface of each coronal pQCT section with the molar 
crowns/roots and the incisor root removed. The lowest trabecular BMD (Tb.BMD) in the OVX 
group compared to the sham group was observed 3.5 mm from the mesial border of M1. There 
was no difference between the sham group and the OVX group Ct.BMD. Additionally, the 
hemimandibles of rats ovariectomized at 26 weeks and maintained for 16 weeks post-OVX were 
scanned via pQCT at one 750 m thick coronal slice through the midpoint of M1 (Figure 3) at an 
in-plane resolution of 100 m [54]. The ROI was the entire surface of the coronal slice with the 
molar crown/roots and the incisor root removed. There was a lower total mandibular BMD in the 
OVX group compared to the sham group.  
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 A long-term study of rats ovariectomized at 13 weeks and maintained for 52 weeks post-
OVX measured changes in mandibular cortical bone thickness [56]. Left hemimandibles were 
exposed to a 70 kV, 7 mA x-ray source and images were digitally captured at a resolution of 12.5 
line pairs/mm with a total image size of 640 by 480 pixels. The ROI was a computer-generated 
contoured shape encompassing the lower mandibular border; it began superiorly where the lower 
border met the incisor root and extended to the most inferior aspect of the lower border. There 
was a lower mandibular Ct.Th in the OVX group compared to the sham group. 
 In summary, the longer the time since OVX, the greater the magnitude of the observed 
changes in AB structure. Likewise the age of the rat at OVX determines its skeletal maturity, and 
thus changes in bone density and structure in a mature rat (> 3 months of age) skeleton is more 
likely to mimic those in a mature adult human skeleton. An immature rat (< 3 months of age) 
skeleton would experience competing skeletal growth after OVX and that may skew any OVX-
induced changes. Robust changes to AB following OVX have consistently been reported in 
studies that analyze mandible outcomes at or after 12 weeks after OVX. The combination of 
studying a rat with a mature skeleton (at least 12 weeks of age (~ 3 months) and ideally closer to 
6 months of age at OVX to exclude skeletal growth) and a time post-OVX of at least 12 weeks, 
would yield changes to AB structure and density that are optimal to represent postmenopausal 
bone loss. Future studies developing interventions to preserve AB should consider this time 
frame. 
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Table 2: Summary of studies investigating mandibular health in rats for 12 weeks or more after OVX 
Rat strain Sample 
size 
per 
group 
Age at 
OVX 
(wks) 
OVX 
duration 
(wks) 
Diet Technology  Main findings for mandible, 
compared to sham control 
Reference 
Wistar n = 5 6 12 1.15 % Ca, 
0.35 % P 
Histomorphometry 24 % decrease in BV [48] 
Wistar n = 15 35 13 0.01 % Ca pQCT 7 % decrease in total BMD 
11 % decrease in Tb.BMD 
1 % decrease in Ct. BMD 
[53] 
Sprague-
Dawley 
n = 6 13 16 Unknown DEXA,  
pQCT 
No change in BMD 
13 % decrease in Tb.BMD 
No change in Ct.BMD 
[55] 
Lewis-
Brown-
Norway 
n = 12 11 16 Unknown µ-CT 18 % decrease in BV/TV 
28 % decrease in Tb.Th 
67 % increase in Tb.Sp 
22 % increase in SMI 
[49] 
Wistar n = 12 26 16 0.1 % Ca pQCT 3 % decrease in total BMD [54] 
Sprague-
Dawley 
n = 11 28 17 1.1 % Ca, 
0.80 % P, 
 
DEXA,  
µ-CT 
No change in BMD 
6 % decrease in Tb.N 
19 % decrease in Conn.D 
No change in BV/TV 
No change in Tb.Th 
[50] 
Sprague-
Dawley 
n = 15 26 29 1.0 % Ca DEXA, 
Histomorphometry 
No change in total or molar 
region BMD 
8 % decrease in bone area 
fraction 
[51] 
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No change in area moment 
of inertia 
Lewis-
Brown-
Norway 
n = 6 13 52 Unknown Radiograph 16 % decrease in Ct.Th [56] 
Fischer n = 6 26 52 1.15 % Ca, 
0.88 % P, 
0.80 IU/g vit 
D3 
µ-CT 75 % decrease in BV/TV 
46 % decrease in Tb.Th 
58 % decrease in Tb.N 
354 % increase in Tb.Sp 
[52] 
BMD, bone mineral density; Tb.BMD, trabecular BMD; Ct.BMD, cortical BMD;  BV, bone volume (2D); BV/TV, bone volume 
(3D); Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; Ct.Th, cortical thickness; SMI, structure 
model index; Conn.D, connective density; DEXA, dual-energy x-ray absorptiometry; pQCT, peripheral quantitative computed 
tomography; µ-CT, micro-computed tomography 
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1.3 Effect of dietary calcium on mandibular health in ovariectomized rats 
 
 In addition to considering age at OVX and time from OVX, dietary Ca levels are also 
important to consider. Two studies [48, 52] used the same level of Ca in the diet (1.15 % Ca) but 
studied the rats for different periods of time post-OVX and reported different percent changes in 
AB volume (24% versus 75%). Thus, the observed differences in AB volume are due to 
differences in the time post-OVX. In other studies that were of similar length after OVX (16 
weeks [54] versus 13 weeks [53]), different dietary Ca levels affected mandibular outcomes. For 
example, a tenfold difference in dietary Ca, of which both levels were considered ‘low Ca’ (0.1 % 
Ca and 0.01% Ca), resulted in a 2.88% and 7.35% decrease in total mandibular BMD, 
respectively. Thus, mandibular health is dependent on the age at OVX, time post-OVX and the 
level of dietary Ca. To control for such variation, future studies could use semi-purified diet such 
as the AIN93M that is specially formulated to meet the nutritional needs of the adult rat [57] and 
facilitates a standardization of the effects of diet on bone outcomes. Although not specifically 
studied in the ovariectomized rat model, other aspects of a diet including macronutrient or 
micronutrient content can also likely affect the outcomes of mandibular health if not tightly 
controlled among studies. 
1.4 ERT therapy preserves mandibular health in ovariectomized rats 
 
 A single human trial has reported higher AB density with ERT [26], yet with the 
ovariectomized rat model it is clear that estrogen treatment can preserve both the periodontium 
[58, 59] and AB density [30, 60] and also reduce mandibular bone turnover [31] (Table 3). Rats 
that were ovariectomized at an unreported age and maintained for two weeks were divided into 
sham, OVX, and OVX + estrogen, and were implanted with mini osmotic pumps to continuously 
deliver either vehicle (sham and OVX groups) or estrogen (OVX + estrogen group) [58]. The 
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treatment that the OVX + estrogen group received was 1.5 g/day of E2; this dose was not 
standardized to body weight so it is difficult to place in the context of the other studies. To 
measure mandibular osteoclastogenesis, right hemimandibles were sectioned into 5 m thick 
slices at the M1 mesial root (Figure 5) and stained for tartrate-resistant acid phosphatase (TRAP) 
activity. The ROI was the buccal periodontium surrounding the mesial root of M1. At two weeks 
post-OVX, there were less nuclei/osteoclast observed in the OVX + estrogen group compared to 
the OVX group. There was no difference in the number of nuclei/osteoclast between the sham and 
OVX + estrogen groups. Thus, estrogen treatment attenuated the OVX-induced 
osteoclastogenesis observed in the rat buccal periodontium of M1.  
  Another study in rats that were ovariectomized at 13 weeks of age, were administered E2 
by injection at a dose of 10 g/kg for 5 days/week, for seven weeks post-OVX [59]. To measure 
the periodontal ligament space, left hemimandibles were cut sagittally at the buccal/lingual 
midpoint (Figure 5) to expose M1-M3, and were scanned via scanning electron microscopy. The 
ROI was the distance between a molar root surface and the supporting AB at three randomly 
chosen sites per rat. There was an increase in the periodontal ligament space between the sham 
and OVX groups. Estrogen treatment inhibited the expansion of the periodontal ligament space, 
and by extension, AB resorption.  
 Rats ovariectomized at 11 weeks received a daily subcutaneous injection of E2 at a dose 
of 20 g/kg for 11 weeks [30]. To measure the AB density, hemimandibles were sectioned into 6 
m thick slices in the coronal plane (Figure 3) between the mesial and distal roots of M1 (Figure 
5). The ROI was the volume of AB within 1000 m of the furcation roof on five equally spaced 
slices within the M1 interradicular septum. There was a lower AB density in the OVX group 
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compared to the sham group. There was no difference in AB density between the sham and the 
OVX + estrogen group.  
 A similar study also used Wistar rats ovariectomized at 11 weeks, but treated the rats with 
an oral dose of estriol at 100 µg/kg, 5 days/week for 12 weeks post-OVX [60]. To measure 
changes in Tb.BMD and bone mineral content (BMC), the hemimandibles were scanned using 
pQCT at a resolution of 100 µm at 11 slices beginning 0.5 mm from the mesial boarder of M1 to 
the distal border of M3 (Figure 3). The ROI extended from the superior edge of the incisor root 
(Figure 6) to the molar furcation roof and excluded the molar crown, roots, and surrounding 
cortical bone. The OVX + estrogen treated group had a higher Tb.BMD and BMC at multiple 
slices compared to the OVX group; the sites of greatest AB preservation were the slices directly 
beneath M1 and M2. 
 To measure longer-term changes in mandibular bone remodeling rats were ovariectomized 
at 13 weeks and left untreated for 52 weeks post-OVX [31]. After the 52 week period, one group 
received estrogen treatment for 10 weeks as a subcutaneous injection of E2 for four days each 
week at a dose of 10 g/kg. Flurochrome bone markers were also administered at 17 and seven 
days prior to necropsy. To measure the mandibular histomorphometry, right hemimandibles were 
sectioned coronally at M2 (Figure 3) into 30 m thick slices and visualized with a fluorescence 
microscope to quantify bone turnover. There were two ROIs, the periosteal bone surface around 
the outside of the mandibular cortical bone, and the endosteal bone surface around the trabeculae 
within the M2 supporting AB. On the periosteal surface, the mineralizing surface of the OVX 
group was higher than the OVX + estrogen group. On the endosteal surface, the double-labeled 
surfaces, mineralizing surfaces, and mineral apposition rates were all higher in the OVX 
compared to the OVX + estrogen group.. 
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 Estrogen treatment reduced osteoclastogenesis, stabilized bone turnover, and therefore 
preserved AB mass in the ovariectomized rat. However, the preservation of AB structure 
following estrogen treatment remains unclear. Future studies should correlate the preservation of 
AB structure following ERT with other key sites rich in trabecular bone that are known to 
respond to ERT in order to place the bone-sparing effects of ERT on AB in the context of 
systemic bone health.
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Table 3: Summary of studies investigating ERT and mandibular health in ovariectomized rats 
Rat strain Sample size 
per group 
Age at 
OVX (wks) 
OVX 
duration 
(wks) 
Estrogen dose; 
duration (wks) 
 
Main findings for mandible, 
compared to OVX 
Reference 
Wistar n = 4 Unknown 2  17 -estradiol 
1.5 g/day 
continuous infusion; 
2 
Less nuclei (osteoclasts) [58] 
Sprague-Dawley n = 5 13 7  17 -estradiol 
10 g/kg 
5 days/wk; 
7 
36 % less periodontal 
ligament space 
[59] 
Wistar n = 14 11 11  17 -estradiol  
20 g/kg daily; 
11 
  
41 % greater bone density [30] 
Wistar n = 15  26 16 Estriol 
100 g/kg 
5 days/wk 
12 
Improved Tb.BMD and 
BMC  
[60] 
Sprague-Dawley n = 9 13  62 17 -estradiol 
10 g/kg  
4 days/wk; 
10 
38 % less periosteal 
mineralizing surface 
88% less endosteal double-
labeled surface 
51% less endosteal 
mineralizing surface 
71% less endosteal mineral 
apposition rate 
[31] 
OVX, ovariectomized; BMD, bone mineral density;  BMC, bone mineral content
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1.5 Objectives 
 
 There are two main study objectives: 
 
1) To quantify the changes to AB structure, density and strength following ERT 
in the OVX rat, a preclinical model of postmenopausal osteoporosis, using µ-
CT. 
2) To investigate the relationship between AB structure, density and strength 
following ERT with trabecular structure and density at the FN and LB3.  
 The aim of these two objectives is to provide strong preclinical evidence that 
the effects of ERT on tooth retention in human studies may, at least in part, be 
explained by the preservation of AB structure. Additionally it will establish the 
magnitude of the response of AB to ERT in the context of other skeletal sites; such 
findings will provide an evidence-based rationale for including AB as a potential 
skeletal site that may be modified by an intervention (i.e. nutritional intervention) 
targeting trabecular bone.   
1.6 Hypotheses 
 
1) ERT will preserve both the structure, density and strength of AB in the 
ovariectomized rat model as assessed by µ-CT. 
2) Preservation of AB will be positively correlated with the known bone-
sparing effects of ERT at the FN and LB3.  
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CHAPTER 2: METHODOLOGY 
 
2.1 Animals 
 
 Ovariectomized Sprague Dawley rats (n = 28) were purchased from Charles 
River Laboratories (Kingston, NY, USA). Prior to arrival, all rats underwent OVX at 
Charles River at 11 weeks of age. Upon arrival at Brock University, rats were 11 
weeks of age and were housed two per cage with a 12:12 hour light/dark cycle and 
were fed AIN93M (TD.94048; Harlan Teklad, Mississauga, ON, Canada) [57] diet 
(Table 4) for the duration of the study. This animal study protocol complied with the 
Canadian Council on Animal Care and was approved by the AUCC at Brock 
University, St. Catharines, Ontario (AUP # 12-09-01).  
Table 4: Composition of AIN93M diet 
Ingredient Amount per kg of diet 
Cornstarch 466 g/kg 
Casein (≥ 85% protein) 140 g/kg 
Dextrinized cornstarch 155 g/kg 
Sucrose 100 g/kg 
Soy bean oil 40 g/kg 
Fiber 50 g/kg 
Mineral mix AIN93M 35 g/kg 
     Calcium 5 g/kg 
Vitamin mix AIN93M 10 g/kg 
     Vitamin D3 1000 IU/kg 
L-Cystine 1.8 g/kg 
Choline bitartrate 2.5 g/kg 
Tert-butylhydroquinone 0.008 g/kg 
Macronutrient summary 
Fat (soybean oil) 40 g/kg (10% total energy) 
Protein (purified casein ≥ 85 protein) 126 g/kg (14% total energy) 
Carbohydrate (sucrose, cornstarch) 727 g/kg (76% total energy) 
 
 
 
32 
 
2.2 Study design 
 
 The ovariectomized rats were randomized into two groups: OVX alone (n = 
14) or estrogen replacement (n = 14). At 12 weeks of age, the estrogen replacement 
group received a subcutaneous pellet that released 1.5 mg of E2 over 90 days 
(Innovative Research of America, Sarasota, FL, USA). The ovariectomized control 
group also received a subcutaneous placebo pellet to compensate for any stress 
endured during the surgical procedure. All pellets were placed using a trochar into a 
subcutaneous pocket created above the right scapula region while the rats were under 
isoflurane anesthesia. After 12 weeks of E2 treatment, both the OVX alone and 
estrogen replacement groups were euthanized by exsanguination under isoflurane 
anesthesia. The study design is summarized in Figure 7. The left and right 
hemimandibles, femurs, and lumbar vertebrae 1-4 were excised, cleaned of soft 
tissue, wrapped in saline soaked gauze, and stored at -80ºC until further analysis.  
 
 
 
 
 
Figure 7: Study design  
The rats were OVX at 11 weeks of age. At 12 wks of age, an E2 or placebo pellet 
was placed. The intervention occurred from 12 through 24 weeks of age. Tissue 
collection occurred at the end of the 12-week intervention.  
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2.2.1 E2 dose 
 
 The E2 was delivered by a slow release pellet that was implanted 
subcutaneously. The pellet delivered 1.5 mg E2 over 90-days, resulting in a daily 
dose of approximately 17 g of E2 or 50 g·kg-1 body weight, assuming an average 
body weight of 340 g based on previous studies.  
2.2.2 Body weight and food intake 
 
 Body weight was measured weekly as a marker for overall health. Food intake 
per cage was measured biweekly. Since the rats were housed two per cage, the cage 
food intake was divided in half and treated as intake per rat.  
2.3 Body composition 
 
 One day prior to euthanization, rats were fasted and body composition was 
measured using dual-energy x-ray absorptiometry (DEXA; pSabre, Orthometrix, 
Naples, FL, USA) to determine bone, lean, and fat mass. The rats were anesthetized 
with isoflurane and placed on the DEXA scanning stage in a prone position. The 
resolution was set at 0.5 x 1.0 cm and the speed at 10 mm/s. Because the area of the 
rat is larger than the scan field, a ROI was measured using specialized software (Host 
Software version 3.9.4; Scanner Software version 1.2.0). The ROI was defined by a 
rectangle 7 cm long and 10 cm wide, beginning at the most proximal aspect of the 
femoral heads thus excluding the hind limbs. The absolute values for bone, lean, and 
fat mass were corrected for differences in body mass within the ROI. This was 
performed by expressing the absolute values as a function of the mass of the ROI and 
multiplying the value by 100%.   
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2.4 Scanning skeletal sites by µ-CT  
 
2.4.1 Sample preparation 
 
 The right hemimandible, left femur, and LB3 were removed directly from 
storage at -80ºC and subsequently wrapped in parafilm to prevent sample dehydration 
during the scan. The wrapped bones were then aligned axially in a foam tube for the 
scan. By placing multiple samples in a foam tube, the samples were scanned 
sequentially in batches; this worked to reduce variation due to scanning. An example 
of the sample set-up is shown in Figure 8.  
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2.4.2 Scanning acquisition and reconstruction parameters 
 
 The scanning parameters for the hemimandible, femur, and LB3 were guided 
by the aim of a minimum sample transmission of 30%. To achieve this aim, the 
Figure 8: Sample preparation for µ-CT 
A hemimandible removed from -80ºC storage (top). The hemimandible was 
wrapped in parafilm and placed axially in a foam tube (middle). The foam tube is 
shown on the scanning platform (used for mice) before entering the scanning field 
(bottom). 
36 
 
voltage, current, and filter selection were optimized for each sample type. 
Additionally, the x-ray exposure time was set to give an average transmission of 60% 
to yield the best image contrast. The rotation step was set at 0.2º to provide the best 
resolution while also achieving a manageable scanning duration of approximately 30 
minutes per sample. The reconstruction of the individual images into a 3D dataset 
was also governed by image quality. Due to the density of the cortical bone 
surrounding the AB, relative to the cortical bone surrounding the FN or lumbar 
vertebral body, there was more noise in the images of the AB. To compensate, a 
higher smoothing factor and a defect pixel masking was applied to reduce noise in the 
AB image slices. All scanning was performed using a Skyscan 1176 µ-CT (Bruker, 
USA) using host software (1176 version 1.1) and reconstruction software (NRECON 
version 1.6.6.0). All scans were set as a 180º rotation around the sample with an 
isotropic voxel size of 9 µm. A summary of the scanning and reconstruction 
parameters for each site is provided in Table 5. 
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Table 5: Scanning acquisition and reconstruction parameters for mandible, femoral 
neck, and lumbar vertebrae 
  Mandible Femoral neck Lumbar 
vertebrae 
Acquisition parameters 
 Voltage (kV) 82 68 68 
 Current (µA) 298 368 368 
 Filter 2 mm Al 1 mm Al 1 mm Al 
 Exposure (ms) 1254 1140 1140 
 Rotation step  0.2º 0.2º 0.2º 
Reconstruction parameters 
 Smoothing 4 1 1 
 Ring artifact 8 8 8 
 Beam hardening 30% 30% 30% 
 Defect pixel mask 3% 0% 0% 
 
2.4.3 Mandible positioning and analysis 
 
 As seen in Figure 9, each mandible scan was reoriented so that a sagittal slice 
at M1 exposed a level furcation roof and a frontal slice at the mesial root showed that 
the root was vertically straight. The images analyzed were the coronal slices passing 
first through the occlusal surface until the molar root apices.  
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As seen in Figure 10, the beginning of the ROI was the slice near the furcation 
roof at which the mesial, distal, lingual, and buccal roots were independent structures 
Figure 9: Mandible positioning at M1 
A sagittal slice through M1 exposed a level furcation roof (right). A frontal slice 
through the mesial root showed that the root was aligned vertically (top). The 
images that were analyzed were the coronal sections proceeding through the AB 
encased by the four roots of M1 (left). 
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surrounding AB. An interpolated shape was drawn contouring the root surfaces in 
contact with the AB of the interradicular septum until the end of the mesial root. 
 
 
As seen in Figure 11 a sub-region of AB between the lingual and buccal roots 
was also drawn. This sub-region was designed to capture larger trabeculae within the 
AB and exclude the dense furcation roof for later 3D BMD analysis. 
 
 
Figure 10: Mandible ROI 
The first slice was the point at which all four roots are independent structures 
(left). The ROI contoured the inner surfaces of the roots to encompass the AB of 
the interradicular septum (middle). The last slice was the point at which the mesial 
root ended (right). 
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2.4.4 Femoral neck positioning and analysis 
 
 Only the proximal aspect of the femur was scanned in order to image the FN. 
The FN site was chosen since changes in BMD at the hip in human studies has 
correlated with an increased likelihood of tooth loss. An aim of this work is to show 
that a similar relationship exists within the OVX rat model between the FN trabecular 
bone and AB so that the OVX rat model can be used in future studies targeting both 
trabecular and AB preservation. As seen in Figure 12, each FN was reoriented so that 
a sagittal slice exposed the neck aligned horizontally and a coronal slice exposed the 
neck aligned vertically. 
 
Figure 11: Three-dimensional alveolar bone ROI with sub-region 
The entire interradicular septum (light blue; center right) and the AB sub-region 
between the buccal and lingual roots (light blue; far right) 
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 The FN ROI began at the last slice to have any femoral head growth plate and 
continue until the FN became continuous with the main proximal femoral medulla 
(Figure 13).  
Figure 12: Femoral neck positioning 
A sagittal slice exposed a FN that is aligned horizontally (right). A coronal slice 
exposed a FN that is aligned vertically (top). A frontal slice exposed the trabecular 
bone within the FN from which an ROI was drawn (left). 
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2.4.5 Lumbar vertebrae positioning and analysis 
 
 As seen in Figure 14, each LB3 was reoriented so that a sagittal slice exposed 
a horizontal vertebral body with a vertical, superior, vertebral growth plate, and a 
coronal slice exposed a vertical vertebral body.  
 
Figure 13: Femoral neck ROI 
The first slice of the ROI was the slice after which the femoral head growth place 
disappeared (left). The ROI continued down the FN (middle). The ROI ended 
when the FN medulla became continuous with the medulla of the femur (right). 
43 
 
 
 
 
 The ROI for LB3 was 200 slices; ± 100 slices from the vertebral body 
midpoint between the two growth plates. A circular primary ROI first captured the 
entire vertebral body and a secondary manually drawn ROI within the cortical bone of 
Figure 14: Lumbar vertebrae positioning 
A sagittal slice exposed a vertebral body that is aligned horizontally with a 
superior vertebral growth plate that is aligned vertically (right). A coronal slice 
exposed a vertebral body that is aligned vertically (top). A frontal slice exposed 
the trabecular bone of the vertebral body that was used for analysis (left). 
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the vertebral body then isolated the trabecular bone used in the analysis. Figure 15 
shows the primary and secondary ROIs. 
 
 
 
2.4.6 µ-CT structure and density parameters 
 
 A global thresholding model was applied to the ROI of the mandible, FN, and 
LB3 body to binarize the trabecular bone structure. Then the following structural 
parameters (described in Table 6) were calculated by the µ-CT specialized software 
(CTan version 1.13.5.1): BV/TV, Tb.Th, Tb.Sp, Tb.N and the SMI. The 3D BMD 
was calculated for the entire ROI and was calibrated against hydroxyapatite phantoms 
in resin that will be described in the next section.  
 
 
Figure 15: Lumbar vertebrae ROI 
A primary ROI isolated the vertebral body from the entire vertebral structure (left). 
A secondary ROI within the boundaries of the cortical bone captured the 
trabecular bone for analysis (right). 
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Table 6: Overview of the three-dimensional structural µ-CT parameters 
Micro-CT parameter Interpretation 
BV/TV (bone volume/tissue volume) 
 
The percent of bone within your 
selected ROI 
Tb.Th (trabecular thickness) The width of the trabecular bone in 3D 
within the ROI 
Tb.Sp (trabecular separation) The width of the space between adjacent 
trabeculae in 3D within the ROI 
Tb.N (trabecular number) The number of discrete trabeculae in 3D 
within the ROI 
SMI (structural model index) A surrogate measure for strength 
specific to the ROI as trabeculae move 
from the strong plate-like shape to the 
weaker rod-like shape 
 
2.5 Phantom calibration 
 
 The phantom calibrations were performed daily during scanning and consisted 
of a water phantom in addition to both a low and high density hydroxyapatite 
phantom. The water phantom was used to calibrate the images for Hounsfield units 
with air equal to -1000 and water equal to 0. The low and high density hydroxyapatite 
phantoms, 0.25 g·cm-3 and 0.75 g·cm-3, respectfully were then used to calibrate 
Hounsfield units to 3D BMD. An example of the three phantoms in a field of view is 
shown in Figure 16. 
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2.6 Biomechanical strength testing 
 
 The left hemimandibles, left femurs and LB3 were all assessed with 
biomechanical strength testing (Instron 4442, Norwood, MA, USA) with specialized 
software (Series IX Automated Materials Tester, version 8.1 5.00). The 
Figure 16: Phantom positioning 
The three phantoms used were: a high density phantom (hydroxyapatite in resin 
0.75 g·cm-3), a low density phantom (hydroxyapatite in resin 0.25 g·cm-3), and a 
small PCR tube filled with distilled water (right; sagittal slice), (top; coronal slice). 
A frontal slice through the low density phantom exposed the surface on which the 
ROI was drawn for 3D density calibration (left).  
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hemimandibles were removed from -80ºC, soaked in phosphate buffered saline (PBS) 
for 2 hours, and then a 3-point bending test was performed. The span width was 10 
mm and the hemimandibles were placed buccal side up with the molar occlusal 
surface facing the operator (Figure 17). The crosshead speed was 2 mm/min and peak 
load was measured.  
 
 
 The femurs were removed from -80ºC, soaked in PBS for 2 hours, and then 
the 3-point bending test was performed. The span width was 15 mm and the femur 
was placed with the anterior surface facing up. The crosshead speed was 2 mm/min 
and peak load was measured.  
Each LB3 was removed from -80ºC, soaked in PBS for 2 hours, and had the 
spinous processes trimmed prior to strength testing. The LB3 was placed on a bottom 
Figure 17: Biomechanical strength testing of mandible 
The left hemimandible was positioned buccal side facing up, across a span width 
of 10 mm, with the crosshead at the midpoint of M1. 
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steel head with the cranial vertebral body surface facing up. A top steel head then 
came into contact with the cranial vertebral body surface to measure peak load before 
compressive failure. 
2.7 Areal BMD and BMC of mandible, femur, and LB1-4 by DEXA 
 
The left hemimandibles were removed from -80ºC and immediately scanned 
with DEXA (Host software 3.9.4/1.2.0, analysis software version 3.9.4). The 
scanning resolution was 0.2 x 0.2 mm with a 5 mm/s scanning speed. A left 
hemimandible (estrogen group, rat #6) was scanned 3 times without repositioning and 
the percent coefficients of variation for whole BMD and BMC were 0.10% and 
0.79%, respectively. The left femurs were removed from -80 ºC and immediately 
scanned with DEXA. The scanning resolution was 0.2 x 0.2 mm with a 10 mm/s 
scanning speed. A left femur (OVX group, rat #14) was scanned 5 times without 
repositioning and the coefficients of variation for the whole BMD and BMC were 
0.68% and 0.73% respectively. Lumbar vertebrae 1 through 4 (LB1-4) were removed 
from -80ºC and immediately scanned with DEXA. The scanning resolution was 0.2 x 
0.2 mm with a 10 mm/s scanning speed. LB1-4 from the OVX group, rat #14 were 
scanned 5 times without repositioning and the coefficients of variation for the whole 
BMC and BMC were 0.52% and 0.47% respectively.  
2.8 Plasma measures of bone remodeling 
 
 Fasted blood samples were collected from the rats under isoflurane anesthesia 
from the tail vein into EDTA coated tubes. The blood was immediately centrifuged at 
2000 x g for 10 minutes at 4ºC and the plasma was aliquoted for storage at -80ºC until 
analysis. Plasma measure of: receptor activator of nuclear factor kappa-B ligand 
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(RANKL), osteoprotegrin (OPG), parathyroid hormone (PTH), osteocalcin, insulin, 
and leptin were obtained using Magpix immunobead assay technology with 
xPONENT software (Luminex Corp., Austin, TX, USA). The kits used were as 
follows:  
 Milliplex MAP Rat RANKL Single Plex Magnetic Bead Kit (RRNKLMAG-
31K-01; Millipore Corp., Billerica, MA, USA) 
 Milliplex MAP Rat Osteocalcin Single Plex Magnetic Bead Kit (RBNMAG-
31K-1OC; Millipore Corp., Billerica, MA, USA) 
 Milliplex MAP Rat Bone Panel 2 Magnetic Bead Kit (RBN2MAG-31K; 
Millipore Corp., Billerica, MA, USA) 
2.9 Statistical analysis 
 
The group body weights and food intake were first analyzed with a 
D’Agostino & Pearson omnibus normality test and were then compared with a two-
way ANOVA. This design accounts for the effects of time and between-group 
differences on body weight and food intake. 
The 3D structure and density parameters (BV/TV, Tb.N, Tb.Th, Tb.Sp, SMI 
and BMD) for each group were first assessed for normality with D’Agostino & 
Pearson omnibus normality test and then compared between groups at each site with a 
parametric or non-parametric t-test. 
To investigate the relationship between AB 3D structure and systemic 
trabecular bone 3D structure, the µ-CT parameters (BV/TV, Tb.N, Tb.Th, Tb.Sp, 
SMI and BMD) were correlated among the mandible, FN, and LB3 body. The groups 
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were first assessed for normality with D’Agostino & Pearson omnibus normality test 
and then were analyzed with a Pearson or Spearman correlation test. 
Group site morphometrics (sample weight, length, height), peak loads and 
areal BMD/BMC were first assessed for normality with a D’Agostino & Pearson 
omnibus normality test and then were compared between groups at each site with a 
parametric or non-parametric t-test. 
The group plasma measures (RANKL, OPG, PTH, osteocalcin, insulin, and 
leptin) were first assessed for normality with D’Agostino & Pearson omnibus 
normality test and then were compared with a parametric or non-parametric t-test. To 
investigate the response of AB to plasma measures of bone remodeling, in reference 
to the well characterized sites of the FN and LB3 body, the BV/TV of the mandible, 
FN, and LB3 body was each correlated with plasma: RANKL, OPG, PTH, 
osteocalcin, insulin, and leptin. 
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CHAPTER 3: RESULTS 
 
3.1 Body weight and food intake during the 12 week E2 intervention  
 
There was an interaction between time and the E2 intervention on the difference between 
group body weights (P < 0.0001). Additionally both time (P < 0.0001) and the intervention (P < 
0.05) each explained a significant amount of the variation in body weight. At week 2 (P < 0.01) 
and weeks 3-4 (P < 0.05) the average body weight of the OVX group was higher than the E2 
group. From weeks 5-12 there was no difference in average body weight between the OVX and 
E2 groups (Figure 18 A). There was an interaction between time and E2 intervention for the 
difference between group food intake (P < 0.0001). Time alone (P < 0.0001) explained a 
significant amount of the variation in the food intake of both groups, but no additional variation 
was explained based on the E2 intervention. Only at one week after the E2 pellet placement did 
the E2 group have a reduced food intake compared to the OVX group (P < 0.0001). There was no 
difference in food intake between the OVX and E2 groups from weeks 2-12. (Figure 18 B). 
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Figure 18: Body weight and food intake 
A) Average body weights and B) Average food intake for each group at weekly 
intervals.  
Results expressed as the mean ± SD 
Differences between OVX and E2: * P < 0.05 
n = 10-14 per group for body weight and food intake 
53 
 
3.2 Regional body composition at the end of the 12 week E2 intervention 
 
At the end of the 12 week E2 intervention, the E2 group had greater areal BMD compared 
to the OVX group and there were no differences in BMC, lean mass, or fat mass (Table 7).  
Table 7: Regional body composition at the end of the 12 week E2 intervention 
 OVX E2 
BMD (g·cm-2) 0.13 ± 0.02 0.15 ± 0.03a 
BMC (g) 2.6 ± 0.6 2.30 ± 0.7 
     Standardized to ROI (%) 1.7 ± 0.3 1.5 ± 0.3 
Lean mass (g) 73.8 ± 11.0 80.1 ± 15.1 
     Standardized to ROI (%) 50.1 ± 12.6 55.2 ± 15.5 
Fat mass (g) 75.3 ± 28.2 67.2 ± 31.6 
     Standardized to ROI (%) 48.3 ± 12.4 43.3 ± 15.3 
Results expressed as the mean ± SD 
OVX, ovariectomized; E2, estrogen replacement 
Differences between OVX and E2 within sites: a P < 0.05 
n = 14 per group 
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3.3 µ-CT structure and density of alveolar bone at mandible, and trabecular bone at 
femoral neck and lumbar vertebrae 
 
 AB of the E2 group had greater BV/TV (P < 0.001), Tb.N (P < 0.05), and Tb.Th (P < 
0.01) compared to the OVX group while AB of the OVX group had greater Tb.Sp (P < 0.01) and 
SMI (P < 0.001) compared to the E2 group. Alveolar  BMD of the E2 group was not greater than 
the OVX group BMD (P = 0.09). BV/TV, Tb.N, and BMD (P < 0.001) of the FN and LB3 was 
greater in the E2 group compared to the OVX group. Tb.Sp and SMI were higher (P < 0.001) at 
both the FN and LB3 in the OVX group compared to the E2 group. There was no difference in 
Tb.Th at the FN or LB3 between the OVX and E2 groups (Table 8). 
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Table 8: Structure and density of alveolar bone of mandible, trabecular bone at the femoral neck, and trabecular 
bone at the lumbar vertebral body 
                       Mandible FN LB3 
 OVX E2 OVX E2 OVX E2 
BV/TV (%) 62.32 ± 5.03 72.10 ± 4.33c 49.16 ± 4.99 61.12 ± 6.60c 23.19 ± 3.11 34.66 ± 3.81c 
Tb.N (mm -1)  2.35 ± 0.15   2.52 ± 0.20a   3.70 ± 0.31    4.36 ± 0.34c   2.29 ± 0.28    3.31 ± 0.28c 
Tb.Th (mm)  0.27  ± 0.02    0.29 ± 0.03b   0.13 ± 0.01 0.14 ± 0.02   0.10 ± 0.01 0.11 ± 0.01 
Tb.Sp (mm)  0.29 ± 0.06b    0.21 ± 0.06   0.21 ± 0.03c  0.16 ± 0.02   0.33 ± 0.04c  0.24 ± 0.03 
SMI  0.15 ± 0.37c  - 0.96 ± 0.58   0.55 ± 0.30c  - 0.89 ± 0.69   1.34 ± 0.23c  0.52 ± 0.27 
BMD (g·cm-3)  0.26 ± 0.09 0.33 ± 0.10   0.50 ± 0.07  0.67 ± 0.09c   0.15 ± 0.06  0.32 ± 0.06c 
Results expressed as the mean ± SD 
OVX, ovariectomized; E2, estrogen replacement; BV/TV, percent BV; Tb.N, trabecular number; Tb.Th, trabecular 
thickness; Tb.Sp, trabecular separation; SMI, structure model index; BMD, BMD 
Differences between OVX and E2 within sites: a P < 0.05; b P < 0.01; c P < 0.001 
n = 14 per group 
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3.3.1 Three-dimensional imaging of alveolar bone in the mandible 
 
 Representative alveolar regions (based on BV/TV) are shown in Figure 19. 
Specifically, the average alveolar region BV/TV in the OVX group was 62.32 % and the 
closest rat alveolar region was OVX rat #2 with a BV/TV of 61.78%. The average 
alveolar region BV/TV in the E2 group was 72.10% and the closest rat alveolar region 
was E2 rat #12 with a BV/TV of 71.74%. The alveolar region ROI from OVX #2 and E2 
#12 are shown in Figure 19 from an inferior view looking up to the furcation roof of M1.  
 
 
 
Figure 19: Representative three-dimensional models of alveolar bone from 
OVX and E2 treated rats  
The alveolar region from the OVX group represents a BV/TV of 61.78% while the 
region from the E2 group represents a BV/TV of 71.74%. 
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3.3.2 Three-dimensional imaging of femoral neck region 
 
 Representative FN regions (based on BV/TV) are shown in Figure 20. 
Specifically, the average BV/TV for the OVX group FN was 49.16% and the rat with the 
closest BV/TV was OVX rat #2 at 48.07%. The average BV/TV for the E2 group FN was 
61.12% and the rat with the closest BV/TV was E2 rat #13 at 61.17%. The 3D FN ROI of 
OVX rat #2 and E2 rat #13 are shown in Figure 20 from a superior view beginning at the 
most proximal aspect of the neck, near the base of the femur head.  
 
 
 
 
 
 
 
 
Figure 20: Representative three-dimensional models of the femoral neck 
region from OVX and E2 treated rats  
The FN region from the OVX group represents a BV/TV of 48.07% while the 
region from the E2 group represents a BV/TV of 61.17%. 
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3.3.3 Three-dimensional imaging of lumbar vertebrae region  
 
 Representative lumbar vertebral body regions (based on BV/TV) are shown in 
Figure 21. Specifically, the average BV/TV for the OVX group LB3 region was 23.19% 
and the rat with the closest BV/TV was OVX rat # 5 at 22.83%. The average BV/TV for 
the E2 group LB3 region was 34.66% and the rat with the closest BV/TV was E2 rat # 8 
at 35.05%. The 3D LB3 region of OVX rat #5 and E2 rat #8 are shown in Figure 21 from 
a superior view.  
 
 
 
3.3.4 Three-dimensional imaging of mandibular alveolar bone, femoral neck and 
lumbar vertebrae regions  
 
 
 Figure 22 shows all of the representative 3D ROI in one image to facilitate 
simultaneous comparison across the multiple sites and between study groups. The E2 
treated ROI appear denser, with smaller marrow spaces, and better connected trabeculae.  
 
Figure 21: Representative three-dimensional models of the lumbar vertebrae 
region from OVX and E2 treated rats  
The LB3 region from the OVX group represents a BV/TV of 22.83% while the 
region from the E2 group represents a BV/TV of 35.05%. 
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Figure 22: Representative three-dimensional models of mandibular alveolar, 
femoral neck, and lumbar vertebrae regions of OVX and E2 treated rats 
The alveolar, FN, and lumbar vertebrae regions (top to bottom) of the OVX (left) 
and E2 (right) treated rats. 
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3.4 Microarchitecture and density of the alveolar bone sub-region as assessed by µ-
CT  
 
 In a sub-region of AB between the apices of the M1 lingual and buccal roots there 
was a greater BV/TV, Tb.Th, (P < 0.001) and BMD (P < 0.05) in the E2 group compared 
to the OVX group. The OVX group had a greater Tb.Sp (P < 0.01) and SMI (P < 0.001) 
compared to the E2 group. There was no difference in Tb.N in the sub-region of AB 
between the OVX and E2 groups (Figure 23). 
 
 
 
Figure 23: Microarchitectural and density differences in the alveolar bone 
sub-region between OVX and E2 treated rats 
Structure and density parameters from µ-CT of AB sub-region. 
A) BV/TV, B) Tb.N, C) Tb.Th, D) Tb.Sp, D) SMI, E) BMD 
*P < 0.05; **P < 0.01; ***P < 0.001 
n = 14 per group 
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3.4.1 Three-dimensional imaging of the mandibular alveolar bone sub-region 
 
 The alveolar sub-region contains only the AB found between the apices of the 
lingual and buccal roots. The sub-regions are from OVX rat #2 and E2 rat # 12 with a 
BV/TV of 54.58% and 72.96%. The sub-regions selected were from the rats with the 
closest average BV/TV to the entire alveolar region, and not from those with the closest 
BV/TV to the average alveolar sub-region. This facilitates a direct comparison between 
the entire alveolar region (Figure 19) and the alveolar sub-region within the same rats 
(Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.5 Correlation among outcomes of alveolar and trabecular bone of the femoral 
neck, and lumbar vertebral body measured by µ-CT   
 
 There was a positive correlation among the BV/TV, Tb.N, Tb.Sp, and SMI of the 
AB region and the BV/TV, Tb.N, Tb.Sp, and SMI of both the FN or LB3. There was no 
correlation between the Tb.Th or BMD of the AB region and the FN. However, there was 
a positive correlation between the Tb.Th and BMD of the AB region and the LB3 (Table 
9).  
 
 
 
 
Figure 24: Representative three-dimensional models of the alveolar sub-
region of OVX and E2 treated rats  
The alveolar sub-region from the OVX group represents a BV/TV of 54.58% 
while the sub-region from the E2 group represents a BV/TV of 72.96%. 
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Table 9: Correlation among outcomes of alveolar and trabecular bone of the 
femoral neck or lumbar vertebrae measured by µ-CT 
 FN    LB3  
AB r P r P 
BV/TV (%) 0.69 < 0.0001 0.75 < 0.0001 
Tb.N (mm-1) 0.42 < 0.05 0.44 < 0.05 
Tb.Th (mm) 0.21 NS 0.42 < 0.05 
Tb.Sp (mm) 0.49 < 0.01 0.63 < 0.001 
SMI  0.73 < 0.0001 0.69 < 0.0001 
BMD (g·cm-3) 0.28 NS 0.47 < 0.05 
BV/TV, percent BV; Tb.N, trabecular number; Tb.Th, trabecular thickness; Tb.Sp, 
trabecular separation; SMI, structure model index; BMD, BMD 
n = 14 per group 
 
 In order to show the clustering of data points between the groups for BV/TV, 
Tb.N, Tb.Sp, and SMI the correlation plots are shown in Figure 25.
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3.6 Biomechanical strength testing and DEXA of mandible, femur, and LB1-4 
(LB3 only for strength testing) 
 
 The OVX hemimandibles were heavier and withstood a greater peak load 
before fracture than the hemimandibles from the E2 group. The hemimandibles of the 
OVX group also had a greater whole BMD and BMC than the hemimandibles of the 
E2 group. There was no difference in femoral weight or length between the groups. 
The femurs from the OVX group withstood a greater peak load before fracture than 
the femurs from the E2 group despite the femurs from the E2 group having a greater 
Figure 25: Correlation plots for structural outcomes between mandible and 
femoral neck or lumbar vertebrae measured by u-CT. 
Correlation plots showing the data distributions for A) BV/TV, B) Tb.Th, C) 
Tb.Sp, D) SMI. 
n = 28 per site 
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areal BMD. There was no difference in femur areal BMC between the groups. There 
was also no difference in LB3 weight between the groups despite the greater height of 
the LB3 from the OVX group compared to the LB3 form the E2 group. No 
differences in LB3 peak load to compressive failure between the groups was detected 
even though the LB3 from the E2 group had a greater areal BMD. There was no 
difference in LB3 areal BMC between the groups (Table 10). 
Table 10: Peak load by biomechanical strength testing and areal BMC and 
BMD by DEXA for mandible, femur, and lumbar vertebrae 
  OVX E2 
Peak load by a materials testing system: 
Mandible    
 Weight (g) 0.72 ± 0.05a 0.67 ± 0.06 
 Peak load (N) 141 ± 14a 128 ± 12 
Femur    
 Weight (g) 1.09 ± 0.09 1.05 ± 0.08 
 Length (mm) 37.3 ± 1.1 36.6 ± 0.7 
 Peak load (N) 154 ± 19c 128 ± 12 
Lumbar Vertebrae    
 Weight (g) 0.60 ± 0.10 0.59 ± 0.07 
 Height (mm) 8.3 ± 0.5a 7.9 ± 0.4 
 Peak load (N) 330 ± 29 305 ± 67 
Areal BMD and BMC by DEXA: 
Whole mandible    
 BMD (g cm-2) 0.16 ± 0.01a 0.15 ± 0.01 
 BMC (g) 0.36 ± 0.02c 0.33 ± 0.02 
Whole femur    
 BMD (g cm-2) 0.22 ± 0.01 0.23 ± 0.02a 
 BMC (g) 0.44 ± 0.03 0.45 ± 0.04 
Lumbar vertebrae    
 BMD (g cm-2) 0.20 ± 0.01 0.21 ± 0.02b 
 BMC (g) 0.47 ± 0.05 0.50 ± 0.06 
Results expressed as the mean ± SD 
OVX, ovariectomized; E2, estrogen replacement 
Differences between OVX and E2 within sites: a P < 0.05; b P < 0.01; c P < 0.001 
n = 12-14 per group 
 
 
3.7 Plasma measures of bone remodeling 
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 There were no differences in plasma RANKL, OPG, PTH, osteocalcin, insulin 
or leptin between the OVX and E2 groups (Table 11).  
Table 11: Plasma measures of bone remodeling 
Analytes (pg ml-1) OVX E2 P value 
RANKL  29 ± 10 23 ± 11 0.08 
OPG 679 ± 390 767 ± 511 0.45 
Osteocalcin 83 ± 38 94 ± 51 0.55 
Insulin 681 ± 438 679 ± 490 0.82 
Leptin 6682 ± 2324 7119 ± 4409 0.71 
PTH 87 ± 30 67 ± 32 0.10 
Results expressed as the mean ± SD 
OVX, ovariectomized; E2, estrogen replacement 
n  = 13-14 per group 
 
 
3.8 Correlation among plasma measurements of bone remodeling and BV/TV at 
mandible, femoral neck and lumbar vertebrae 
 
 There was a negative correlation between plasma RANKL concentration and 
BV/TV at the FN and LB3 but not at the mandible (P = 0.11) (Figure 26 A). There 
was also a negative correlation between plasma PTH concentration and BV/TV at the 
LB3 but not at the mandible (P = 0.09) and FN (P = 0.08) (Figure 26 B). 
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Figure 26: Correlation plots of RANKL and PTH with BV/TV at the 
mandible, femoral neck, and lumbar vertebrae   
Correlation plots showing the data distributions for A) RANKL and B) PTH 
n  = 27-28 per site 
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CHAPTER 4: DISCUSSION 
 
4.1 Main study findings: 
 
 Estrogen treatment attenuated the OVX-induced resorption of mandibular AB. 
The first objective of this research was to quantify the AB structure, density and 
strength following ERT. Estrogen treatment preserved the AB structure and density in 
the mandible of ovariectomized rats. The E2 treated group had, on average, a 9.8%, 
12.0% and 11.5% higher BV/TV at the AB region, FN, and LB3 respectively 
compared to the OVX alone group. The density of an AB sub-region was also greater 
in the E2 treated group. The second objective was to investigate the relationship 
between AB following ERT and trabecular bone at the FN and LB3. The BV/TV of 
the AB region positively correlated with the BV/TV of the FN and LB3.  
4.2 Mechanism of estrogen-mediated effects on AB: 
 
 In the maxillary AB of female rats treated with E2 (1.25 mg/kg), there was a 
reduction in osteoclast area, the number of nuclei per osteoclast, and the length of the 
osteoclast resorption surface with a higher number of smaller, mononucleated 
osteoclasts and smaller bone resorption surfaces [61]. E2 treatment effectively 
increased osteoclast apoptosis in the AB of the female rats [61]. Osteoclasts also 
exhibit a greater expression of estrogen receptor β in estrogen treated rats, suggesting 
a direct effect of the E2 on the osteoclasts located in the AB [62]. It is therefore likely 
that E2 reduces osteoclastic activity in the AB surrounding the first mandibular molar 
and, given that in our study design the serum E2 level was likely supraphysiological, 
it is probable that any increase in the rate of bone turnover caused by OVX in our 
estrogen treated rats was practically ablated. This proposed effect is supported by the 
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fact that our estrogen treated rat lumbar vertebral BV/TV was within a few percentage 
points of the lumbar vertebral BV/TV of sham treated rats from a different study [63].  
4.3 Comparing our observed structural of both the alveolar bone of the mandible 
and the trabecular bone of the lumbar vertebral body to a single study that also 
investigated both sites but between sham and OVX groups: 
 
 The structure and density of both the AB of the mandible and the trabecular 
bone of the lumbar vertebral body was measured between sham and OVX groups at 
12 weeks post-OVX [64]. Compared to our study design the rats used were older (6 
months versus 3 months of age at OVX) and the lumbar vertebrae and mandible were 
scanned at a lower resolution (17 µm versus 9 µm). Both the lumbar vertebral body 
and mandibular AB ROI were similar to those used in our study, the lumbar vertebrae 
was based on the midpoint of the vertebral body and the AB was the entire 
interradicular septum of M1 ending at the mesial and distal root apices. By 12 weeks 
post-OVX there was a 17.6% difference in BV/TV at the lumbar vertebral body 
between the sham and OVX groups while our study found only a 11.5% difference in 
BV/TV between the E2 treated and OVX groups. However, by 12 weeks post-OVX 
no difference in mandibular AB BV/TV between the sham and OVX groups was 
reported despite a difference in SMI and trabecular pattern factor (Tb.Pf). With 
additional time post-OVX more deleterious changes to the AB occurred, by 24 weeks 
there was a difference in Tb.Th, connective density (Conn.D), and degree anisotropy 
and by 36 weeks a greater Tb.Sp. The small sample size used (n = 3 vs. n = 14) and 
the lower resolution µ-CT (17 µm vs. 9 µm) compared to our study likely contributed 
to the lack of a significant difference in BV/TV at the AB region between the sham 
and OVX groups. This theory is supported by the fact that there was a significant 
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difference in BMD in the same ROI reported at weeks 24 and 36 post-OVX with no 
significant difference in BV/TV at either of those times points. This study builds on 
the argument that AB, just like the trabecular bone of the lumbar vertebral body, is 
responsive to OVX and that changes to AB can be quantified with µ-CT. 
4.4 DEXA and biomechanical strength testing are not specific enough to detect 
OVX-induced changes to alveolar bone: 
 
Both DEXA and biomechanical strength testing were unable to reflect the 
changes in AB micro-architecture detected with µ-CT. The greater peak loads 
accepted by hemimandibles and femur midpoints of the OVX group were likely 
caused by longitudinal bone growth [65]. Such growth was likely disrupted in the E2 
treated group, and was supported by the greater weight and height of the 
hemimandibles and LB3 respectively of the OVX group. Despite differences in 
growth, the parameters provided by µ-CT analysis showed significant differences in 
structure at the AB region, FN, and LB3. Although the AB region is not without its 
challenges even when assessed by µ-CT, examples include a relatively small ROI and 
high BV/TV compared to other sites, which are reflected in the fact that most of our 
SMI values are negative. SMI normally ranges from 0 to 3 representing a transition 
from plate-like to rod-like trabeculae within the ROI respectively [66]. A negative 
SMI is difficult to interpret but indicates very dense samples with concave plate-like 
trabeculae [67]. However, in the context of this study, it is the strong correlation 
among the sites in relation to the differences in their SMI that is the most important 
since it again emphasizes the sensitivity of AB to systemic skeletal changes. 
The hemimandible and femur midpoints were stronger in the OVX group than 
the E2 treated group despite the femurs of the E2 treated rats having a greater areal 
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BMD. It is important to note that although the hemimandibles weighed more and the 
third lumbar vertebral bodies were taller from the OVX group compared to the E2 
treated group, there were no differences in ROI size at any site used in the µ-CT 
analysis based on tissue volume (results not shown). Therefore the µ-CT results, 
unlike those from DEXA and biomechanical strength testing, are not biased by an 
increased bone size since there was no difference in ROI size between groups. 
4.5 Effect of estrogen treatment in multiple skeletal sites after OVX: 
 
 To date, only one published study correlated mandibular AB with a site in the 
systemic skeleton; the proximal tibia [68]. As in our study, adult Sprague-Dawley rats 
were ovariectomized for 3 months and the mandibles and tibia were subjected to µ-
CT and biomechanical strength testing. The estrogen treated rats received 10 µg/kg 
E2 by injection every other day for the 3 months post-OVX. The scan resolution was 
comparable to ours (10 µm vs. 9 µm) although the AB ROI differed from ours and 
extended from the incisor crest to the apices of the roots of M1 instead of just the 
interradicular septum of M1. In the study Tb.Th and Tb.Sp were correlated between 
the AB region and the proximal tibia; while in our study Tb.Th only correlated 
between the AB region and the LB3 but not the FN, and Tb.Sp correlated among the 
AB, FN and LB3. The study reported that the AB region BS/BV was correlated (r = 
0.85) with the BS/BV of the proximal tibia and similarly in our study the AB region 
BV/TV was correlated at both the FN (r = 0.69) and LB3 (r = 0.75). Our study 
findings are thus in agreement and expand the literature by including sites clinically 
relevant for fracture. We observed our strongest correlations between the AB and 
LB3 at all parameters analyzed, and this is likely due to the reduced longitudinal 
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growth of the LB3 relative to a site such as the proximal tibia. Both this study and 
ours measured BMD with a µ-CT which is different from the areal BMD measured by 
DEXA. Areal BMD represents a two-dimensional picture of the mineral content, but 
not structure, of a bone ROI while BMD measured using µ-CT measures the density 
of a 3D structure within a ROI. In this study the higher BMD in the estrogen treated 
rats did not reach significance (1.24 vs. 1.32 g·cm-3) that is consistent with our 
findings (0.26 vs. 0.33 g·cm-3) keeping in mind that the differences in density are 
conserved despite the different ROI characteristics. Unlike our strength data, the 
estrogen treatment was trending on an improvement in peak load when testing the 
alveolar process below the molars instead of the midpoint of M1. Although the 
mandible micro-architecture was not directly compared between the sham, OVX, and 
E2 treated groups, the positive correlation with the proximal tibia and the fact that the 
tibia showed improvements in micro-architecture with E2 treatment support our 
findings that the AB of the mandible responds positively to estrogen treatment.  
4.6 Characterization of the study estrogen dose: 
 
 The three most commonly used methods of estrogen administration in 
ovariectomized rat trials are: direct daily injection [69], subcutaneous slow release 
pellet placement [70], and estrogen taken orally in a matrix [71]. The best method is 
estrogen taken orally in a matrix (one example of a matrix is E2 in hazelnut cream 
spread) because it mimics the oral ERT taken by patients and results in serum levels 
of E2 that are both stable and within physiological limits [71]. In our study we used a 
slow-release pellet containing 1.5 mg of E2 to deliver approximately 17 µg of E2 per 
day for 90 days. The subcutaneous slow release pellet method was chosen because it 
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was designed to deliver a consistent daily estrogen dose without the time demands 
and stress on the animals of a daily injection. However, recent evidence suggests that 
the amount of estrogen released from the subcutaneous pellets is inconsistent over the 
duration claimed by the manufacturer [69-71]. We did notice a decrease in the food 
intake in the estrogen treated rats at week one and a lower body weight from weeks 
two through four without reduced food intake compared to the OVX group. It is likely 
that these changes in food intake and body weight are due to the estrogen 
intervention, since such changes were not observed in the OVX group that had a 
placebo pellet placed to account for the stress of the pellet placement surgery. It is 
logical that a reduced food intake would result in a reduced body weight, however, 
despite a reduction in food intake during week 1 alone following E2 pellet placement, 
there was a reduction in body weight between the E2 treated and OVX groups at 
weeks two, three and four of the study. Since there was no difference in food intake 
between the E2 treated and OVX groups during those weeks (weeks two through 
four), the difference in body weight is likely caused by the estrogen intervention. 
Additionally, because there is no difference in body weight past week four, it appears 
that whatever characteristic about the estrogen intervention that was causing the 
difference in body weight had ceased. This information indicates that the estrogen 
dose may not have been uniform across the treatment intervention and that a large 
amount of estrogen was released from the pellets at the beginning of the study. This 
inference is supported by a study that characterized the release of E2 from pellets 
identical to those used in this research, (1.5 mg, 90 slow release, from Innovative 
Research of America) and also in Sprague-Dawley rats that were of a similar age to 
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the ones used in our study (14 versus 12 weeks of age at OVX) [69]. Compared to a 
daily injection of 15 µg of E2, the serum concentrations in the pellet treated group 
were 73% higher at two weeks and 580% higher at four weeks than the injection 
group. A steady state in serum E2 was achieved two weeks earlier in the injection 
group compared to the pellet group.  
 In a follow-up study using a slow release pellet designed to give a daily dose 
of 4 µg for 60 days, much less than our 17 µg dose, it was found that the serum E2 
concentration was highest two days after pellet placement and decreased over a 42 
day observation period, but never to physiological E2 levels observed in intact rats. 
[70]. Even a much smaller dose slow release pellet designed to give a daily dose of 1 
µg E2 for 90 days peaked at a concentration above the 4 µg per day pellet at two days 
after placement (528.0±51.5 pg/mL vs. 304.9±34.6 pg/mL; not statistically compared) 
and steadily declined until from days 35 to 42 the concentration was not significantly 
greater than ovariectomized controls. The injection group of 10 µg/kg E2 did not 
yield concentrations that were higher than the physiological range of rats euthanized 
during the normal estrus cycle (5.9–63.1 pg/mL) for the duration of the experiment 
[70]. 
 In an experiment investigating the short-term effects of exogenous E2 
administration (ranging from 30 minutes to seven days following treatment), the 
injection group (10 µg/kg) achieved physiological levels within four hours while the 1 
µg per day pellet had an initial concentration ~ 30 times the physiological range and 
took seven days to achieve physiological levels. The 4 µg per day pellet never 
achieved serum levels within the physiological range even after seven days [71]. 
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Although ERT or HRT in patients may commonly result in levels of serum estrogen 
higher than physiological levels, it should be noted that the aim of this study is not to 
recommend ERT or HRT as a strategy for tooth retention. It is unrealistic to 
extrapolate the dose of E2 used in this study to a current form of ERT or HRT given 
differences in the different mode of delivery (subcutaneous pellet vs. oral 
administration/transdermal patch) and potential inconsistent release of drug from the 
pellet. The purpose of this study is to highlight the responsiveness of AB to a known 
bone sparing agent, E2, and provide a rationale for using the ovx rat for developing 
dietary strategies that preserve bone at multiple skeletal sites, including the mandible. 
 Since our study used a slow release pellet which was designed to give a daily 
dose that was approximately four times greater (17 µg vs. 4 µg) than the 0.25 mg, 60 
day slow release pellet previously described [71], it is likely that our estrogen treated 
rats experienced a spike in E2 concentration immediately following pellet placement 
and may only have achieved physiological levels near the end of the experiment. Just 
as in our study, when Sprague-Dawley rats were injected with 10 µg/kg E2 for 35 
days they also experienced a reduced body weight and a reduction in longitudinal 
bone growth [65]. Since the estrogen dose used in our study was even higher - 
designed to release approximately 50 µg/kg E2 per day - and given the potential for 
an even higher daily dose than planned in the beginning of the study based on the 
characterized performance of the slow release pellets, it is likely that the reduced 
body weight observed in the estrogen treated rats and also the reduction in bone size 
(longitudinal bone growth) was caused by a high estrogen exposure. 
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4.7 Strengths and Limitations: 
 
4.7.1 Strengths:  
 
1. Large sample size: As seen in Tables 1-3, it is common for studies to use 
sample sizes less than 10 per group and even less than five per group. Our 
relatively large sample size substantiates our findings. For example, the 
change in BV/TV following ERT was a key determinant of AB preservation 
and based on our sample size of n = 14 the study was powered well over 99% 
to detect the observed difference between the means.  
2. Standardized rodent diet: We chose a rodent diet that has been specifically 
developed to meet the nutritional requirements of mature rats [57] and thus 
have controlled for the influence of diet on the OVX-induced changes to AB. 
The relationship between mandibular density and dietary Ca (Section 1.3) 
highlights the importance of using a consistent diet in future studies. Future 
researchers can adopt AIN93M when attempting to reproduce the relationship 
between OVX and AB loss expressed in this work.  
3. Multiple measurement techniques: We have used state-of-the-art µ-CT to 
precisely quantify changes to bone micro-architecture. Additionally we have 
investigated the relationship shown by µ-CT with more traditional 
measurements of total mineral content by DEXA and peak load until fracture 
by biomechanical strength testing. Plasma measures of bone remodeling were 
also assessed by multiplexing so that the localized changes to bone micro-
architecture could be placed in the context of the systemic skeleton.  
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4. Correlations with bone turnover markers highlight preclinical model validity: 
In the clinical setting an increase in PTH has been associated with an increase 
in fracture incidence [72] which is in line with sustained levels of PTH 
stimulating bone turnover and resulting in bone catabolism [73]. Increased 
RANKL has not associated with fracture incidence [74] but an increase in 
RANKL is an indicator of increased osteoclastogenesis [75]. In our preclinical 
model the negative correlation between BV/TV at LB3 and plasma PTH levels 
supported the clinical increase in fracture risk. In terms of RANKL the 
BV/TV of both the LB3 and FN negatively correlated with the plasma 
RANKL levels, highlighting the expected inverse relationship between bone 
micro-architecture and osteoclastogenesis. 
4.7.2 Limitations:  
 
1. Lack of sham group: A limitation to our study design was the lack of a sham 
animal group which would both: account for any continued longitudinal bone 
growth that may be masking the effects of the OVX, and assess the efficacy of 
the estrogen intervention compared to an intact rat. An intact rat would 
facilitate the direct comparison between the effects of endogenous vs. 
exogenous estrogen on mandibular AB and provide a benchmark to compare 
the effects of the estrogen treatment in the context of physiological estrogen 
levels. A recent study with a similar design to ours contained only sham and 
OVX groups and assessed bone loss at multiple sites [63]. The rats were 
ovariectomized at 12 weeks of age as in our study and changes in trabecular 
micro-architecture were assessed at multiple skeletal sites including the third 
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and fourth lumbar vertebral bodies; this is an important site because it can be 
directly compared to changes we observed at L3. The µ-CT unit and scanning 
parameters were also very similar; they used a Skyscan 1072 at a 19 µm 
resolution while our study used a Skyscan 1176 at a 9 µm resolution. By 15 
weeks post-OVX there was a significant difference in BV/TV between the 
sham (32.33 ± 4.14 %) and OVX (21.97 ± 1.03 %) groups. This is similar to 
the difference in BV/TV observed at 12 weeks post-OVX in our study 
between the E2 treated (34.66 ± 3.81 %) and OVX groups (23.19 ± 3.11%). 
Since our study did not include a sham group to compare the efficacy of the 
E2 treatment, this study is important because it suggests that our E2 treatment 
preserved the trabecular micro-architecture at the lumbar vertebral bodies to 
sham values; the BV/TV in our study of E2 treated rats was 34.66 % which is 
very close to the 32.33 % reported for the sham rats.  
2. Characteristics specific of the ovariectomized rat model to consider when 
studying changes in AB: A limitation to the rat model for studying AB 
turnover is the fact that rat molars migrate distally throughout the lifespan 
[76]. This means that bone modeling occurs predominately on the mesial 
surfaces of the tooth while constant remodeling occurs on the distal surfaces 
[77]. Human teeth also migrate throughout life, but typically in the mesial 
direction [78]. OVX has been shown in the rat to accelerate AB turnover [79]. 
3. Inconsistent delivery of E2 from subcutaneous pellet: A limitation of the study 
was the potential for a spike in plasma E2 levels experienced by the rats when 
the pellets were first placed. Current research [71] into novel matrices to 
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administer E2 orally hold promise, but again this technique does not mimic all 
types of ERT available such as the transdermal patch..
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CHAPTER 5: CONCLUSIONS 
 
1) ERT preserved both the structure and density of the AB as determined by µ-CT 
in the preclinical model of postmenopausal osteoporosis. 
2) The AB structure and density following ERT were correlated with the structure 
and density of trabecular bone at the FN and LB3.  
5.1 Implications: 
 
 Estrogen treatment preserved the structure and density of mandibular AB in 
the preclinical rat model of postmenopausal osteoporosis. Differences in AB were 
mirrored by differences at the FN and LB3, which represent well-characterized sites 
of postmenopausal bone loss and subsequent fragility fracture. These correlations 
make a strong argument that an intervention – such as a drug or diet or supplement – 
to improve bone structure and density targeting these key sites of fracture may have 
beneficial effects on AB and thus tooth retention. Increased tooth retention is linked 
with better nutritional status [14, 16, 18, 19] and a healthful diet that supports overall 
skeletal health while reducing the risk of chronic disease [28]. Tooth loss and 
osteoporosis both occur with aging and thus clinical interventions aimed at bone 
preservation will benefit AB [80]. The mandible is not isolated from the rest of the 
skeleton, and to date AB turnover in the ovariectomized rat has been reduced by 
bisphosphonate (alendronate [30] and risedronate [31]) treatment, and AB formation 
has been stimulated by calcitonin [31] and intermittent PTH treatment [81]. Based on 
the capacity of the AB to characteristically respond to estrogen therapy in the context 
of well-characterized sites of postmenopausal bone loss, this preclinical model clearly 
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demonstrates its utility and importance in the development of future drug and 
nutritional interventions aimed at improving dental clinical practice with a special 
focus on tooth retention and thus the reduction of chronic disease. 
CHAPTER 6: FUTURE DIRECTIONS 
 
To strengthen the link between ERT and the preservation of AB in the 
ovariectomized rat model this study design could be replicated with the inclusion a 
sham group. This would help characterize the response of the AB to the ERT in the 
context of an unaltered control and account for any continued longitudinal bone 
growth.  
Additionally, this proposed preclinical model of AB loss has centered around 
sex hormone deficiency in women and in the future should be expanded to include 
sex hormone deficient men represented with the orchidectomized rat model. To fully 
eliminate the competing influences of continued skeletal growth in the adult rat 
model, an aged rat (approximately six months) would ideally be used. Both of these 
critiques of the animal model bring the real purpose of the use of animal models into 
focus; the model is to best represent the human population that will directly benefit 
from the study intervention. Tooth loss is an age related phenomenon and the patients 
seeking restorative dental work are likely aged and thus in a state of sex hormone 
deficiency. By including orchidectomized rats into study designs and using a more 
aged model future studies can best represent the characteristics of the population 
likely to be encountered in clinical practice. 
 Since the aim of this preclinical model is to accurately represent changes to 
AB in an aged, sex hormone deficient clinical population it can be readily applied to 
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research involving implant placement and guided tissue regeneration. Estrogen 
deficiency has been shown to have systemic deleterious effects on the skeleton in this 
model, but it is important to keep in mind that the oral microenvironment is highly 
specialized [78] and therefore presents unique challenges to future drug or nutritional 
interventions. Understanding how factors such as the chronic inflammation 
characteristic of periodontal disease and other comorbidities interact is key to 
optimizing systemic skeletal therapy for the targeting of AB. The integration of AB 
preservation into existing systemic skeletal therapy is likely difficult, but the 
preclinical animal model presented in this work represents an attempt to bridge the 
gap, since there is clearly a relationship between the health of AB and the trabecular 
bone of the long bones and spine.  
 Nutrition is a modifiable lifestyle risk factor that represents a convergence 
among systemic bone health, AB health, tooth loss, and the risk of chronic disease. 
Clearly future preclinical studies aimed at improving AB health must use a 
multifaceted approach that considers both systemic skeletal health as well as 
individual lifestyle factors such as nutrition. Only then can inferences relevant to 
clinical practice be developed into effective strategies targeting an improved quality 
of life and reduce the risk of chronic disease. 
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